18/03/2021 |
ABDALA Clinical Study - Phase III |
CIGB |
Registered |
18/05/2018 |
Gastricel-I |
CIDEM |
Registered |
18/06/2021 |
CIMAvax-EGF®-post-COVID19 convalescent with respiratory disorders-adults-Phase II (CORVAXCIM) |
CIM |
Registered outdated |
18/06/2021 |
ior®EPOCIM in post-COVID-19 convalescent patients with cardiovascular, renal and/or respiratory disorders |
CIM |
Registered outdated |
19/03/2021 |
SOBERANA - INTERVENTION |
FINLAY |
Registered |
19/05/2023 |
To evaluate the immunogenicity and safety of SOBERANA® 02 and SOBERANA® Plus as booster of immunity against the omicrom variant of SARS-CoV-2, in adult subjects |
FINLAY |
Registered |
19/09/2020 |
BIOMODULINA T in a long-lived population at high risk of COVID-19 infection |
BIOCEN |
Registered |
19/11/2015 |
EFFECTIVENESS AND SAFETY IN GENERIC ABACAVIR/LAMIVUDINE AND EFAVIRENZ IN HIV NAIVE PATIENTS |
CLS |
Registered |
19/11/2020 |
NeuroEPO-Ataxia-Adults-Phase III |
CIM |
Registered outdated |
20/03/2022 |
Antioxidant efcts of Abexol in middle-aged and older subjects |
CPN |
Registered outdated |
20/04/2022 |
Jusvinza in rheumatoid arthritis |
CIGB |
Registered |
20/09/2013 |
Prevenox on osteoarthritis |
CPN |
Registered |
20/09/2013 |
Abexol + Prevenox in Osteoarthritis |
CPN |
Registered |
20/09/2022 |
NeuroEPO in mild-moderate Alzheimer's disease |
CIM |
Registered |
20/10/2021 |
CIMAvax-EGF/Lung cancer/Biomarkers/Prospective CT |
CIM |
Registered |
20/11/2019 |
Enhanced recovery protocols in cardiac surgery protocols |
HHA |
Registered |
2008-07-29 |
Gallbladder retractor and Knot pusher with simultaneous coaxial traction : new laparoscopic instruments. |
CNCMA |
Registered |
2008-07-29 |
Post marketing clinical trial to evaluate the reactogenicity profile of the Cuban vaccine against diphtheria, tetanus, and pertussis infections in infants. |
FINLAY |
Registered |
2008-07-29 |
A phase I/II study to evaluate the Salmonella Typhi Vi polysaccharide vaccine – vax-TyVi – in children and teenagers. |
FINLAY |
Registered |
2008-07-29 |
Clinical trial to evaluate the safety, reactogenicity and immunogenicity of the vax-TyVi vaccine in volunteers between 18 and 20 years of age. |
FINLAY |
Registered |